A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 18-30

  Tian, Hong Lei ^a   Yu, Ting ^b   Xu, Nai Ning ^a   Feng, Chao ^a   Zhou, Li Ying ^a   Luo, Hou Wei ^c   Chang, Donald C ^a   Le, Xiao Feng ^d   Luo, Kathy Qian ^b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b Nanyang Technological University   (Singapore)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer drug; Apoptosis; Breast cancer; Reactive oxygen species; Tanshinone IIA

Indexed keywords

ACETYLTANSHINONE IIA; CASPASE 3; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; GALLIC ACID PROPYL ESTER; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TANSHINONE IIA; UNCLASSIFIED DRUG; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PHENANTHRENE DERIVATIVE; TANSHINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALVIA MILTIORRHIZA; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; HEPG2 CELL LINE; HL 60 CELL LINE; IC50; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROTEIN TRANSPORT; SOLUBILITY; SYNTHESIS; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HELA CELLS; HEP G2 CELLS; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NEOPLASMS; PACLITAXEL; PHENANTHRENES; PROPYL GALLATE; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; SOLUBILITY; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS; DITERPENES, ABIETANE;

MUS; SALVIA MILTIORRHIZA;

EID: 77956231164     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.020     Document Type: Article

References (42)

1. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
2. Cragg G.M., Newman D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 100:72-79.
3. Gordaliza M. Natural products as leads to anticancer drugs. Clin. Transl. Oncol. 2007, 9:767-776.
4. Luo K.Q., Yu V.C., Pu Y., Chang D.C. Application of the fluorescence resonance energy transfer method for studying the dynamics of caspase-3 activation during UV-induced apoptosis in living HeLa cells. Biochem. Biophys. Res. Commun. 2001, 283:1054-1060.
5. Tian H., Ip L., Luo H., Chang D.C., Luo K.Q. A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine. Br. J. Pharmacol. 2007, 150:321-334.
6. Xia Z., Gu J., Ansley D.M., Xia F., Yu J. Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease. J. Thorac. Cardiovasc. Surg. 2003, 126:1404-1410.
7. Wang X., Morris-Natschke S.L., Lee K.H. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med. Res. Rev. 2007, 27:133-148.
8. Wu W.L., Chang W.L., Chen C.F. Cytotoxic activities of tanshinones against human carcinoma cell lines. Am. J. Chin. Med. 1991, 19:207-216.
9. Ryu S.Y., Lee C.O., Choi S.U. In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza. Planta. Med. 1997, 63:339-342.
10. Sung H.J., Choi S.M., Yoon Y., An K.S. Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp. Mol. Med. 1999, 31:174-178.
11. Liu J.J., Lin D.J., Liu P.Q., Huang M., Li X.D., Huang R.W. Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J. Biomed. Sci. 2006, 13:813-823.
12. Yuan S.L., Huang R.M., Wang X.J., Song Y., Huang G.Q. Reversing effect of tanshinone on malignant phenotypes of human hepatocarcinoma cell line. World J. Gastroenterol. 1998, 4:317-319.
13. Lee W.Y., Liu K.W., Yeung J.H. Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett. 2009, 285:46-57.
14. Wang X., Wei Y., Yuan S., Liu G., Lu Y., Zhang J., Wang W. Potential anticancer activity of tanshinone IIA against human breast cancer. Int. J. Cancer 2005, 116:799-807.
15. Su C.C., Lin Y.H. Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. Int. J. Mol. Med. 2008, 22:847-851.
16. Wang J., Wang X., Jiang S., Yuan S., Lin P., Zhang J., Lu Y., Wang Q., Xiong Z., Wu Y., Ren J., Yang H. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J. Neurooncol. 2007, 82:11-21.
17. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83:757-766.
18. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
19. Adam S.A., Marr R.S., Gerace L. Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors. J. Cell Biol. 1990, 111:807-816.
20. Luo K.Q., Chang D.C. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem. Biophys. Res. Commun. 2004, 318:303-310.
21. Porter A.G., Janicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999, 6:99-104.
22. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121.
23. Yu D., Liu B., Tan M., Li J., Wang S.S., Hung M.C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996, 13:1359-1365.
24. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 1999, 15:269-290.
25. Desagher S., Martinou J.C. Mitochondria as the central control point of apoptosis. Cell Biol. 2000, 10:369-377.
26. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
27. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15:2922-2933.
28. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
29. Finucane D.M., Bossy-Wetzel E., Waterhouse N.J., Cotter T.G., Green D.R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J. Biol. Chem. 1999, 274:2225-2233.
30. Hao H., Wang G., Cui N., Li J., Xie L., Ding Z. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr. Drug Metab. 2007, 8:137-149.
31. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51:794-798.
32. Oberley L.W., Buettner G.R. Role of superoxide dismutase in cancer: a review. Cancer Res. 1979, 39:1141-1149.
33. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic. Biol. Med. 1990, 8:583-599.
34. Baker A.M., Oberley L.W., Cohen M.B. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 1997, 32:229-233.
35. Oberley T.D., Oberley L.W. Antioxidant enzyme levels in cancer. Histol. Histopathol. 1997, 12:525-535.
36. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell Biochem. 2008, 104:657-667.
37. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
38. Hug H., Strand S., Grambihler A., Galle J., Hack V., Stremmel W., Krammer P.H., Galle P.R. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. Biol. Chem. 1997, 272:28191-28193.
39. Bragado P., Armesilla A., Silva A., Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
40. Tsang W.P., Chau S.P., Kong S.K., Fung K.P., Kwok T.T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 2003, 73:2047-2058.
41. Mizutani H., Oikawa S., Hiraku Y., Murata M., Kojima M., Kawanishi S. Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper(II) and NADPH-cytochrome P450 reductase. Cancer Sci. 2003, 94:686-691.
42. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp. Mol. Med. 2006, 38:535-545.